Penumbra Inc (NYSE:PEN) has been downgraded to Hold in a report by Zacks Investment Research today.
- Updated: October 14, 2016
Zacks Investment Research has downgraded Penumbra Inc (NYSE:PEN) to Hold in a statement released on 10/15/2016.
Previously on 10/13/2016, Zacks Investment Research reported about Penumbra Inc (NYSE:PEN) raised the target price from $0.00 to $80.00. At the time, this indicated a possible upside of 0.12%.
Yesterday Penumbra Inc (NYSE:PEN) traded -0.48% lower at $71.27. The company’s 50-day moving average is $73.25 and its 200-day moving average is $61.93. The last stock close price is up 14.53% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 111,403 shares of the stock were exchanged, down from an average trading volume of 252,585
See Chart Below
Penumbra Inc has a 52 week low of $35.31 and a 52 week high of $79.49 with a P/E ratio of 921.17 The company’s market cap is currently $0.
About Penumbra Inc (NYSE:PEN)
Penumbra, Inc. (Penumbra) is an interventional therapies company. The Company designs, develops, manufactures and markets medical devices. The Company has a portfolio of products that addresses medical conditions and significant clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. The Company focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Ischemic Stroke, Neurovascular Embolization and Neurosurgical Tools. The Company's peripheral vascular products include Peripheral Embolization and Peripheral Thrombectomy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.